Clinical Investigation of the Next-Generation Intraocular Lenses

Completed · Not applicable

Conditions studied: Cataract

In brief

This study is a 6-month, prospective, multicenter, subject/evaluator-masked, bilateral, randomized clinical investigation of the TECNIS Next-Generation Model ZFR00 and Model ZYR00 IOLs versus the TECNIS Multifocal Model ZLB00 control IOL. The study will be conducted at up to 14 sites in the U.S.A and will enroll up to 260 subjects to achieve approximately 220 randomized and bilaterally-implanted subjects, resulting in approximately 195 evaluable subjects (65 in each test group and 65 in the control group) at 1 and 6 months. Subjects are to be implanted with the same IOL in both eyes, the ZFR00 IOL, the ZYR00 IOL or the ZLB00 control IOL. The eye implanted first will be considered the primary study eye.

Key facts

Study ID: NCT03372434
Run by: Abbott Medical Optics
People needed: 225
Starts: 2018-01-16
Expected to finish: 2018-10-30
Last updated by the study team: 2025-06-24

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Minimum 22 years of age
Bilateral cataracts for which posterior chamber IOL implantation has been planned
Preoperative best corrected distance visual acuity (BCDVA) of 20/40 Snellen or worse with a glare source or 20/40 Snellen or worse without a glare source
Potential for postoperative BCDVA of 20/30 Snellen or better
Corneal astigmatism:
Normal corneal topography
Preoperative corneal astigmatism of 1.00 D or less in both eyes
Clear intraocular media other than cataract in each eye
Availability, willingness and sufficient cognitive awareness to comply with examination procedures
Signed informed consent and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries
Ability to understand and respond to a questionnaire in English

You may not qualify if…

Requiring an intraocular lens power outside the available range of +14.0 D to +26.0 D
Any clinically-significant pupil abnormalities (non-reactive, fixed pupils, or abnormally-shaped pupils)
Irregular corneal astigmatism
Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.)
Prior corneal refractive (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery. Note: Prophylactic peripheral iridotomies and peripheral laser retinal repairs that, in the opinion of the investigator will not confound study outcome or increase risk to the subject, are acceptable.
Corneal abnormalities such as stromal, epithelial or endothelial dystrophies that are predicted to cause visual acuity losses to a level worse than 20/30 Snellen during the study
Inability to achieve keratometric stability for contact lens wearers (per procedure outlined in Section 10.3)
Recent ocular trauma or ocular surgery that is not resolved/stable or may affect visual outcomes or increase risk to the subject
Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that are predicted to cause visual acuity losses to a level worse than 20/30 Snellen during the study
Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration or tilt, such as pseudoexfoliation, trauma, or posterior capsule defects
Use of systemic or ocular medications that may affect vision
Prior, current, or anticipated use during the course of the 6-month study of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) that may, in the opinion of the investigator, confound the outcome or increase the risk to the subject (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract surgery)
Poorly-controlled diabetes
Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the opinion of the investigator, would increase the operative risk or confound the outcome(s) of the study (e.g., immunocompromised, connective tissue disease, suspected glaucoma, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.). Note: controlled ocular hypertension without glaucomatous changes (optic nerve cupping and visual field loss) is acceptable.
Known ocular disease or pathology that, in the opinion of the investigator,
may affect visual acuity
may require surgical intervention during the course of the study (macular degeneration, cystoid macular edema, diabetic retinopathy, uncontrolled glaucoma, etc.)
may be expected to require retinal laser treatment or other surgical intervention during the course of the study (macular degeneration, cystoid macular edema, diabetic retinopathy, etc.)
Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with the fluctuation of hormones that could lead to refractive changes
Concurrent participation or participation within 60 days prior to preoperative visit in any other clinical trial
Desire for monovision correction

Where it is running

Empire Eye & Laser Center — Bakersfield, California, United States
Katzen Eye Care and Laser Center — Boynton Beach, Florida, United States
Chesapeake Eye Care & Laser Center — Annapolis, Maryland, United States
Eye Doctors of Washington — Chevy Chase, Maryland, United States
Scott & Christie and Associates, PC — Cranberry Township, Pennsylvania, United States
Carolina EyeCare Physicians, LLC — Mt. Pleasant, South Carolina, United States
Loden Vision Centers — Goodlettsville, Tennessee, United States
Eye Specialty Group — Memphis, Tennessee, United States
Texas Eye and Laser Center — Hurst, Texas, United States
Lehmann Eye Center — Nacogdoches, Texas, United States
Focal Point Vision — San Antonio, Texas, United States
Clarus Eye Centre — Lacey, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.